Oncology Xagena
Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...
The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta ), tyrosine kinase inhibitor, met both primary endpoints of ...
In a phase 1b trial, Avelumab ( Bavencio ) plus Axitinib ( Inlyta ) as first-line had encouraging antitumor activity for patients with advanced renal cell carcinoma ( aRCC ) ( Lancet Oncol 2018;19:451 ...
The FDA ( Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Inlyta ( Axitinib ), a tyrosine kinase inhibitor, for the first-line treatme ...
Patients with advanced B3 thymoma ( B3T ) and thymic carcinoma ( TC ) resistant to chemotherapy have limited treatment options. Treatment with anti-PD1 showed not negligible toxicity and limited act ...
The randomized, open-label, phase 3 KEYNOTE-426 study has demonstrated that Pembrolizumab ( Keytruda ) + Axitinib ( Inlyta ) significantly improved overall survival ( OS ), progression-free survival ( ...
